ReviewCell biochemistry and biophysics2026
Thymoquinone as a Multi-Target Modulator of Inflammatory and Immunometabolic Signaling: Mechanisms and Therapeutic Implications.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymoquinone, the principal bioactive constituent of Nigella sativa, has been extensively investigated for its anti-inflammatory, antioxidant, and metabolic effects. However, these activities are often examined separately, limiting understanding of their broader biological integration. This review examines thymoquinone through three interconnected immunometabolic axes: NF-κB-mediated inflammation, AMPK/mTOR-driven metabolic regulation, and ROS/Nrf2-dependent redox balance. Preclinical evidence indicates that thymoquinone modulates each of these pathways and may influence the crosstalk linking oxidative stress, metabolic reprogramming, and inflammation. Based on these findings, we propose a conceptual framework positioning thymoquinone as a multi-target immunometabolic modulator. This framework is hypothesis-generating and requires further validation through integrated experimental and clinical studies.
Indexed as
Identifiers
42709396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.